Acne Biomarker Profiling for Severity and Microbiome Balance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for acne vulgaris focus on symptom alleviation rather than complete cure, and there is a lack of understanding of the pathological mechanisms, leading to dysbiosis of the skin microbiome and resistance issues with antimicrobial drugs.

Innovation Solution

Development of a biomarker for predicting the occurrence, aggravation, and determining the severity of acne vulgaris through human transcriptome and microbiome analysis, identifying specific human genes and bacterial pathways associated with acne severity, and a screening method for skin microbiome-improving substances.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antimicrobial drugs are used to treat acne vulgaris, then symptoms are alleviated, but dysbiosis of the skin microbiome occurs and resistant bacteria develop

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidmicrobiome dysbiosis and bacterial resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and identifies specific biomarkers (human genes and bacterial pathways) that are directly associated with acne pathogenesis and microbiome status. By focusing on these specific extracted elements rather than broad antimicrobial treatment, the method enables targeted monitoring and intervention that addresses acne while preserving microbiome balance.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent implements a feedback mechanism by using identified biomarkers to monitor treatment response and microbiome status. This feedback loop allows for adjusting treatment strategies to maintain microbiome homeostasis while effectively managing acne, preventing the dysbiosis that occurs with conventional antimicrobial therapy.

Inventive Principle:

Principle #23Feedback

2Reliability

If conventional treatments focus on symptom alleviation, then acute symptoms are reduced, but complete cure and prevention of recurrence are not achieved

Engineering Contradiction:

Improvesymptom controlVSAvoidtime to achieve complete cure and prevention

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by identifying and monitoring biomarkers that indicate early pathogenic changes and treatment response. This early detection capability allows for intervention before symptoms fully develop or recur, enabling preventive treatment strategies that address the root causes of acne rather than merely treating visible symptoms.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent employs a dynamic monitoring approach using biomarkers that change over time in response to treatment and disease progression. This dynamic assessment allows for real-time adjustment of treatment strategies, optimizing the balance between symptom control and preventing recurrence, thereby reducing the overall time to achieve complete cure.

Inventive Principle:

Principle #15Dynamics

3Loss of information

If the pathological mechanism of acne vulgaris is not fully understood, then treatment strategies are limited, but further research and analysis are required

Engineering Contradiction:

Improveunderstanding of pathological mechanismVSAvoidcomplexity of analysis methodology

Core Design Contradiction:

Loss of informationVSDevice complexity

Solution Approach 1:

The patent replaces complex, resource-intensive traditional research methods with biomarker-based molecular analysis. By substituting extensive clinical observation and experimentation with targeted measurement of specific genes and pathways, the study efficiently uncovers pathological mechanisms while managing analytical complexity through focused biomarker selection.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentEP4592388A1Biomarker for use in prediction of occurrence of acne vulgaris, prediction of severity and determination of severity

Publication Date: 2025.07.30 ROHTO PHARM CO LTD

AI summary

Disclosed is a biomarker for use in the prediction of the occurrence and the severity of acne vulgaris, and in the determination of the severity of acne vulgaris.